AB Corporate Bond ETF (NASDAQ:EYEG) Short Interest Up 1,233.3% in August

AB Corporate Bond ETF (NASDAQ:EYEG) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 1,040 shares, a growth of 1,233.3% from the August 15th total of 78 shares. Based on an average daily volume of 668 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.0% of the company’s stock are short sold.

AB Corporate Bond ETF Stock Performance

Shares of AB Corporate Bond ETF stock traded down $0.01 during trading on Friday, hitting $34.00. 20 shares of the company’s stock traded hands, compared to its average volume of 299. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07. AB Corporate Bond ETF has a 1 year low of $33.99 and a 1 year high of $36.63. The stock has a market capitalization of $27.20 million, a P/E ratio of -20.24 and a beta of 0.18. The business has a 50-day simple moving average of $34.62 and a 200-day simple moving average of $35.08.

AB Corporate Bond ETF Cuts Dividend

The business also recently announced a monthly dividend, which was paid on Friday, September 4th. Shareholders of record on Tuesday, September 1st were paid a dividend of $0.1284 per share. The ex-dividend date was Tuesday, September 1st. This represents a c) annualized dividend and a yield of 4.5%. AB Corporate Bond ETF’s dividend payout ratio is currently -101.79%.

Institutional Trading of AB Corporate Bond ETF

A hedge fund recently raised its stake in AB Corporate Bond ETF stock. Jane Street Group LLC boosted its stake in shares of AB Corporate Bond ETF (NASDAQ:EYEG) by 166.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,741 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,839 shares during the period. Jane Street Group LLC owned about 2.10% of AB Corporate Bond ETF worth $563,000 at the end of the most recent reporting period. 64.16% of the stock is currently owned by institutional investors.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.